The HER2-positive gastric cancer treatment landscape has undergone profound transformation, evolving from a specialized therapeutic area into a cornerstone of modern precision oncology. This remarkable metamorphosis is fueled by advanced comprehension of HER2 molecular biology, innovative antibody-drug conjugate (ADC) breakthroughs, and widespread regulatory endorsement across global markets....